NNN

NEXTGEN BIOMED LTD

No trades
See on Supercharts

NXGN fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Nextgen Biomed Ltd. operates as a research and development company. Its primary product is Eyepen, a smart and modular device consisting of pens for injecting insulin, and helps users self-manage the treatment of diabetes by documenting the times and doses of taking insulin by injection. The company was founded on December 26, 1990 and is headquartered in Raanana, Israel.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

NXGN does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company